ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO451

Serum Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1) Associates with Decline in Estimated Glomerular Filtration Rate (eGFR) Slope in a Phase 2 Study of Selonsertib in Diabetic Kidney Disease (DKD)

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Tarrant, Jacqueline, Gilead Sciences, Foster City, California, United States
  • Billin, Andrew, Gilead Sciences, Inc., Foster Cuty, California, United States
  • Xiao, Yuanyuan, Gilead Sciences, Foster City, California, United States
  • Peach, Matthew, Gilead Sciences, Inc., Foster Cuty, California, United States
  • Chen, Fang, Gilead Sciences, Foster City, California, United States
  • Patterson, Scott D., Gilead Sciences, Inc., Foster Cuty, California, United States
  • Sundy, John, Gilead Sciences, Inc, Belmont, California, United States
  • Patel, Uptal D., Gilead Sciences, Inc., Foster Cuty, California, United States
  • Pergola, Pablo E., Renal Associates, PA, San Antonio, Texas, United States
  • Chertow, Glenn Matthew, Stanford University School of Medicine, Palo Alto, California, United States

Circulating sTNFR1 is a promising biomarker of DKD severity and risk of progression. We investigated the disease associations and predictive effect of sTNFR1 in a Phase 2 study of selonsertib (SEL), a small molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in DKD.


In this study, 333 patients with moderate-to-advanced DKD (UACR 600 mg/g for stage 3a, UACR 300 mg/g for stage 3b, UACR 150 mg/g for stage 4) were randomized 1:1:1:1 to receive SEL (2, 6, or 18 mg) or matching placebo (PBO) orally once daily for 48 weeks (W48). The analysis population (full analysis set) excluded 2 sites for technical deviations and patients with baseline eGFR 20 mL/min/1.73m2. Serum sTNFR1 was measured at baseline (BL) and W48 by ELISA. Spearman correlation was used to assess association between markers, and a random slope model for differences in chronic eGFR slope (W4-W48) between treatments.


Serum sTNFR1 was inversely correlated with eGFR at BL (N=261; r=-0.74; p<0.001) and at W48 (N=215; r=-0.75; p<0.001), in addition to change of sTNFR1 and change of eGFR at W48 (N=215; r=-0.35; p=0.0016). There was no significant relation between sTNFR1 and UACR at BL (N=261; r=0.12). We found a trend for a relatively lower increase in sTNFR1 from BL to W48 in the 18mg SEL group (median=0.12 ng/mL, Q1-Q3: -0.43 to 0.53 ng/mL; N=49) compared to PBO (median=0.31 ng/mL, Q1-Q3: -0.17 to 0.66 ng/mL; N=49). Applying a BL 4.3 ng/mL sTNFR1 cutpoint retrospectively (identified by Yamanounchi M, et al. Kidney Int 2017), 51% of our overall population were potentially at high risk for progression to end stage renal disease. The subgroup >4.3 ng/mL sTNFR1 had an apparent therapeutic benefit from SEL 18 mg compared to PBO when comparing eGFR chronic slope (W4 to 48) difference (p=0.029), however this was no different from the benefit shown overall (p=0.036).


Serum sTNFR1 was directly correlated with eGFR at BL and change at W48 in patients with moderate-to-advanced DKD. The subgroup with BL sTNFR1>4.3 ng/mL had similar treatment benefit to SEL compared to the overall trial population


  • Commercial Support